eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank
5/2018
vol. 35
 
Share:
Share:
more
 
 
abstract:
Original paper

Omalizumab improves forced expiratory volume in 1 second in patients with severe asthma

Krzysztof Pałgan, Magdalena Żbikowska-Götz, Kinga Lis, Elżbieta Chrzaniecka, Zbigniew Bartuzi

Adv Dermatol Allergol 2018; XXXV (5): 495-497
Online publish date: 2018/07/19
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Asthma is a multiphenotypic disease, and therapeutic managenment in patients with severe asthma is particulary difficult, with conventional treatment of severe asthma showing poor efficacy.

Aim
To analyse forced expiratory volume in 1 s (FEV1) following the adminstration of omalizumab.

Material and methods
Six patinents (mean age: 50 ±12.6) with severe, uncontrolled asthma according to the GINA guidelines were enrolled in the study.

Results
Treatment with omalizumab increased in all subjects FEV1 by 17.28 ±13.4% after months and 18.57 ±13.4% after 12 months of treatment.

Conclusions
These results provides further evidence that therapy with omalizumab improves spiromtric parameters in severe asthma.

keywords:

asthma, omalizumab, spirometry, forced expiratory volume in 1 s

Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe